{"pmid":32434431,"title":"Cardiovascular disease, heart failure and COVID-19.","text":["Cardiovascular disease, heart failure and COVID-19.","J Renin Angiotensin Aldosterone Syst","Faconti, Luca","Chowienczyk, Philip J","Shah, Ajay M","32434431"],"journal":"J Renin Angiotensin Aldosterone Syst","authors":["Faconti, Luca","Chowienczyk, Philip J","Shah, Ajay M"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434431","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1177/1470320320926903","topics":["Mechanism","Treatment","Diagnosis"],"weight":1,"_version_":1667521393689886720,"score":9.490897,"similar":[{"pmid":32248966,"pmcid":"PMC7102656","title":"The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease.","text":["The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease.","Coronavirus disease 2019 (COVID-19), caused by a novel betacoronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first described in a cluster of patients presenting with pneumonia symptoms in Wuhan, China, in December of 2019. Over the past few months, COVID-19 has developed into a worldwide pandemic, with over 400,000 documented cases globally as of March 24, 2020. The SARS-CoV-2 virus is most likely of zoonotic origin, but has been shown to have effective human-to-human transmission. COVID-19 results in mild symptoms in the majority of infected patients, but can cause severe lung injury, cardiac injury, and death. Given the novel nature of COVID-19, no established treatment beyond supportive care exists currently, but extensive public-health measures to reduce person-to-person transmission of COVID-19 have been implemented globally to curb the spread of disease, reduce the burden on healthcare systems, and protect vulnerable populations, including the elderly and those with underlying medical comorbidities. Since this is an emerging infectious disease, there is, as of yet, limited data on the effects of this infection on patients with cardiovascular disease, particularly so for those with congenital heart disease. We summarize herewith the early experience with COVID-19 and consider the potential applicability to and implications for patients with cardiovascular disease in general and congenital heart disease in particular.","Int J Cardiol","Tan, Weiyi","Aboulhosn, Jamil","32248966"],"abstract":["Coronavirus disease 2019 (COVID-19), caused by a novel betacoronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first described in a cluster of patients presenting with pneumonia symptoms in Wuhan, China, in December of 2019. Over the past few months, COVID-19 has developed into a worldwide pandemic, with over 400,000 documented cases globally as of March 24, 2020. The SARS-CoV-2 virus is most likely of zoonotic origin, but has been shown to have effective human-to-human transmission. COVID-19 results in mild symptoms in the majority of infected patients, but can cause severe lung injury, cardiac injury, and death. Given the novel nature of COVID-19, no established treatment beyond supportive care exists currently, but extensive public-health measures to reduce person-to-person transmission of COVID-19 have been implemented globally to curb the spread of disease, reduce the burden on healthcare systems, and protect vulnerable populations, including the elderly and those with underlying medical comorbidities. Since this is an emerging infectious disease, there is, as of yet, limited data on the effects of this infection on patients with cardiovascular disease, particularly so for those with congenital heart disease. We summarize herewith the early experience with COVID-19 and consider the potential applicability to and implications for patients with cardiovascular disease in general and congenital heart disease in particular."],"journal":"Int J Cardiol","authors":["Tan, Weiyi","Aboulhosn, Jamil"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32248966","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.ijcard.2020.03.063","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Mechanism","Prevention","Treatment"],"weight":1,"_version_":1666138490935443457,"score":48.317913},{"pmid":32462267,"title":"Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation.","text":["Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation.","Coronavirus diseases 2019 (COVID-19) has become a worldwide pandemic affecting people at high risk and particularly at advanced age, cardiovascular and pulmonary disease. As cardiovascular patients are at high risk but also have dyspnea and fatigue as leading symptoms, prevention, diagnostics and treatment in these patients are important to provide adequate care for those with or without COVID-19 but most importantly when comorbid cardiovascular conditions are present. Severe COVID-19 with acute respiratory distress (ARDS) is challenging as patients with elevated myocardial markers such as troponin are at enhanced high risk for fatal outcomes. As angiotensin-converting enzyme 2 (ACE2) is regarded as the viral receptor for cell entry and as the Coronavirus is downregulating this enzyme, which provides cardiovascular and pulmonary protection, there is ongoing discussions on whether treatment with cardiovascular drugs, which upregulate the viral receptor ACE2 should be modified. As most of the COVID-19 patients have cardiovascular comorbidities like hypertension, diabetes, coronary artery disease and heart failure, which imposes a high risk on these patients, cardiovascular therapy should not be modified or even withdrawn. As cardiac injury is a common feature of COVID-19 associated ARDS and is linked with poor outcomes, swift diagnostic management and specialist care of cardiovascular patients in the area of COVID-19 is of particular importance and deserves special attention.","Clin Res Cardiol","Bohm, Michael","Frey, Norbert","Giannitsis, Evangelos","Sliwa, Karen","Zeiher, Andreas M","32462267"],"abstract":["Coronavirus diseases 2019 (COVID-19) has become a worldwide pandemic affecting people at high risk and particularly at advanced age, cardiovascular and pulmonary disease. As cardiovascular patients are at high risk but also have dyspnea and fatigue as leading symptoms, prevention, diagnostics and treatment in these patients are important to provide adequate care for those with or without COVID-19 but most importantly when comorbid cardiovascular conditions are present. Severe COVID-19 with acute respiratory distress (ARDS) is challenging as patients with elevated myocardial markers such as troponin are at enhanced high risk for fatal outcomes. As angiotensin-converting enzyme 2 (ACE2) is regarded as the viral receptor for cell entry and as the Coronavirus is downregulating this enzyme, which provides cardiovascular and pulmonary protection, there is ongoing discussions on whether treatment with cardiovascular drugs, which upregulate the viral receptor ACE2 should be modified. As most of the COVID-19 patients have cardiovascular comorbidities like hypertension, diabetes, coronary artery disease and heart failure, which imposes a high risk on these patients, cardiovascular therapy should not be modified or even withdrawn. As cardiac injury is a common feature of COVID-19 associated ARDS and is linked with poor outcomes, swift diagnostic management and specialist care of cardiovascular patients in the area of COVID-19 is of particular importance and deserves special attention."],"journal":"Clin Res Cardiol","authors":["Bohm, Michael","Frey, Norbert","Giannitsis, Evangelos","Sliwa, Karen","Zeiher, Andreas M"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462267","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s00392-020-01656-3","keywords":["corona","covid-19","cardiovascular risk","heart failure","hypertension","myocardial injury"],"topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1668079521332461569,"score":43.03797},{"pmid":32360242,"title":"COVID-19 Illness and Heart Failure: A Missing Link?","text":["COVID-19 Illness and Heart Failure: A Missing Link?","JACC Heart Fail","Mehra, Mandeep R","Ruschitzka, Frank","32360242"],"journal":"JACC Heart Fail","authors":["Mehra, Mandeep R","Ruschitzka, Frank"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360242","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.jchf.2020.03.004","keywords":["covid-19","catecholamines","heart failure","hyperinflammation","myocarditis"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495879479296,"score":41.61409},{"pmid":32252591,"pmcid":"PMC7188058","title":"COVID-19 and the Heart.","text":["COVID-19 and the Heart.","Infection with the severe acute respiratory syndrome novel coronavirus produces a clinical syndrome known as 2019 novel coronavirus disease (COVID-19). When severe, COVID-19 is a systemic illness characterized by hyperinflammation, cytokine storm, and elevations of cardiac injury biomarkers. Here, we review what is known about the pathophysiology of COVID-19, its cardiovascular manifestations, and emerging therapeutic prospects. In this rapidly moving field, this review was comprehensive as of April 3, 2020.","Circ Res","Akhmerov, Akbarshakh","Marban, Eduardo","32252591"],"abstract":["Infection with the severe acute respiratory syndrome novel coronavirus produces a clinical syndrome known as 2019 novel coronavirus disease (COVID-19). When severe, COVID-19 is a systemic illness characterized by hyperinflammation, cytokine storm, and elevations of cardiac injury biomarkers. Here, we review what is known about the pathophysiology of COVID-19, its cardiovascular manifestations, and emerging therapeutic prospects. In this rapidly moving field, this review was comprehensive as of April 3, 2020."],"journal":"Circ Res","authors":["Akhmerov, Akbarshakh","Marban, Eduardo"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32252591","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1161/CIRCRESAHA.120.317055","keywords":["biomarkers","cardiovascular diseases","coronavirus","inflammation","myocarditis"],"topics":["Diagnosis","Treatment","Mechanism"],"weight":1,"_version_":1666138493080829952,"score":41.36094},{"pmid":32383758,"title":"SARS-CoV-2 receptor ACE2 expression in the human heart: cause of a post-pandemic wave of heart failure?","text":["SARS-CoV-2 receptor ACE2 expression in the human heart: cause of a post-pandemic wave of heart failure?","Eur Heart J","Thum, Thomas","32383758"],"journal":"Eur Heart J","authors":["Thum, Thomas"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32383758","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1093/eurheartj/ehaa410","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666419683363913728,"score":40.65236}]}